NCT06590207View on ClinicalTrials.gov

Convalescent Plasma for the Treatment of Patients With WNV - a Double- Blind Randomized Controlled Study

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 4, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

March 30, 2025

Conditions
West Nile Fever With Neurologic Manifestation (Diagnosis)West Nile Fever Without Complications
Interventions
DRUG

plasma rich with WNV neutralizing antibodies

200 ml plasma of the convalescents: produced in the blood bank, from the blood of Sheba workers who participated in the SPRI study (Helsinki 0196-23) and whose blood was found to have neutralizing antibodies to WNV above 1:524. The blood units from the volunteers who will donate will meet all the requirements of a normal blood donation and will only include men or women who were not pregnant, and the units will pass all the tests accepted at the blood bank before donation.

DRUG

Saline

Placebo

Trial Locations (1)

5265601

Sheba Medical Center, Ramat Gan

All Listed Sponsors
lead

Sheba Medical Center

OTHER_GOV

NCT06590207 - Convalescent Plasma for the Treatment of Patients With WNV - a Double- Blind Randomized Controlled Study | Biotech Hunter | Biotech Hunter